Recent 8-K filings for PMHS
Highest-materiality recent filing
Trustfeed Corp. to acquire Polomar Specialty Pharmacy via merger; Polomar members to own 75% of combined company
- Each 1% of Polomar membership converts to 357,414 shares of Trustfeed common stock; no fractional shares.
- Post-merger, Polomar members own 75% of Trustfeed; current stockholders own 25%.
-
Directors David Spiegel and Terrence M. Tierney resigned; Tierney remains interim CEO.
-
Polomar Health appoints Douglas Beck as CFO and Treasurer effective July 15, 2026
Douglas Beck appointed CFO and Treasurer, also serving as principal financial and accounting officer.
-
Polomar Health Services dismisses GreenGrowth CPAs, appoints Haskell & White as new auditor
Dismissed GreenGrowth CPAs effective July 8, 2026; no outstanding work remains.
-
Polomar Health Services overhauls board, appoints new Executive Chairman and officers
David Spiegel and Terrence Tierney resigned as directors; Tierney remains Interim CEO.
-
Polomar Health Services terminates merger with Altanine, ends patent license
Merger agreement terminated as of June 12, 2026; deal no longer in best interests of shareholders.
-
Polomar Health waives five merger conditions with Altanine; CEO Tierney to step down upon closing
Polomar and Altanine waive conditions including S-4 effectiveness, Nasdaq listing, $25M equity line, reverse split to $10, and concurrent financing.
-
ForHumanity terminates exclusive marketing deal with Polomar; Polomar disputes claims
ForHumanity Agreement allowed exclusive marketing of certain pharmaceutical products; guaranteed $750K payment, $500K paid.
-
Polomar amends ForHumanity deal; sets revenue milestones for exclusivity through 2028
Second Amendment effective Dec 5, 2025; initial exclusivity extended to June 30, 2025.
-
Polomar Health amends Altanine merger exchange ratio: 1:1 common, 5:1 preferred
Amendment dated Oct 8, 2025 adjusts Exchange Ratio: 1 share Parent Common per Company Common share.
-
Guaranteed payments of $750K; $200K already received, with remaining $500K due by Oct 31, 2025.
-
Polomar Health Services merges with Altanine; Altanine shareholders to own 80% of combined company
Merger Sub to merge into Altanine; Altanine survives as wholly owned subsidiary.
-
Up to $150,000 borrowing capacity with CWR 1, LLC; initial $60,000 drawn upon signing.
-
Entered Registration Rights Agreements with Reprise Management and CWR 1, LLC on July 18, 2025, effective June 30, 2025.
-
Reprise note principal reduced to $597,549 using $300K preferred stock proceeds; maturity extended from July 2025 to July 2027; interest reduced to 12%.
-
Polomar Health posts $1.3M net loss on $58.8K revenue; CFO resigns, 10-K delayed
Terrence Tierney resigned as Treasurer and interim CFO; Charlie Lin appointed CFO and Treasurer at $130K salary.
-
Polomar Health signs exclusive distribution deal for inhalable sildenafil and sumatriptan
Agreement with ForHumanity Health and Island 40 Group grants exclusivity through Sep 30, 2025, in exchange for $750,000 guaranteed revenue.
-
Polomar Health restates Q3 2024 financials; acquisition reclassified as recapitalization
SEC comment letter prompted reclassification of Sep 30, 2024 acquisition from reverse merger to recapitalization.
-
Polomar Health amends license with Pinata; adds pharmacy sub, sets royalties of 10-20%
Amended license covers metformin (10% royalty), semaglutide/liraglutide (20%), sumatriptan/sildenafil (15%).
-
Polomar Health Services assumes $633K promissory note at 12-15% interest in acquisition
Upon acquiring Polomar Specialty Pharmacy, assumed $633,430 outstanding on unsecured promissory note to Reprise Management.
-
Polomar Health Services acquired 100% of Polomar Specialty Pharmacy on September 30, 2024 in exchange for common stock.
-
Company changed its name from Trustfeed Corp. to Polomar Health Services, Inc. effective October 10, 2024.
-
Trustfeed Corp. completes reverse merger acquisition of Polomar Specialty Pharmacy
Acquired 100% of Polomar Specialty Pharmacy in exchange for ~207.4M shares of common stock.
-
Trustfeed Corp. issues 10M shares upon conversion of 500K preferred shares to CRW 1, LLC
On Sept 12, 2024, Trustfeed issued 10M common shares to CRW 1, LLC upon full conversion of 500K Series A Convertible Preferred shares.
-
Trustfeed Corp. enters $250K promissory note with affiliate CWR 1 LLC
Initial draw $157,622.56 used to repay prior undocumented loans from same lender.
-
Trustfeed Corp. appoints Gabriel Del Virginia as director effective July 18, 2024
Gabriel Del Virginia, 66, appointed to fill board vacancy; term until next annual meeting.
-
Trustfeed Corp. shareholders approve name change, reverse split, and equity plan
Written consent from stockholder holding ~82.87% of common and all Series A preferred (84.3% voting power) approved all proposals.
-
Trustfeed Corp. licenses patent-pending IP from affiliate Pinata Holdings for drug delivery products
Royalty rates: 10% for metformin, 15% for sumatriptan/sildenafil, 20% for semaglutide/liraglutide on net sales.
-
Each 1% of Polomar membership converts to 357,414 shares of Trustfeed common stock; no fractional shares.
-
Brett Rosen resigned from all positions (President, CFO, Secretary, Treasurer, sole director) on March 21, 2024; no disagreements.
-
Trustfeed Corp. director Rasmus Refer resigns effective February 12, 2024
Rasmus Refer resigned as director effective February 12, 2024.
-
Fastbase sold 90,437,591 common shares (~83% of outstanding) and 100% of Series A Preferred to CWR 1 LLC for $350,000.
-
Trustfeed Corp. dismisses Gries & Associates, engages GreenGrowth CPAs as new auditor
Gries sold its business to GreenGrowth CPAs; Trustfeed dismissed Gries effective Oct 9, 2023.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material